Intraneuronal Aβ as a trigger for neuron loss: Can this be translated into human pathology?

Biochemical Society Transactions

Volumn 39, Issue 4, 2011, Pages 857-861

  Bayer, Thomas A ^a   Wirths, Oliver ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alzheimer's disease (AD); Amyloid peptide (A ); Amyloid precursor protein (APP); Human pathology; Intraneuronal amyloid peptide (intraneuronal A ); Neuron loss

Indexed keywords

9D5 ANTIBODY; AMYLOID BETA 42; AMYLOID BETA PE3 42; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; EPHRIN RECEPTOR B2; GLOBULOMER; GLUTAMIC ACID; GLUTAMINYL CYCLASE; LOW MOLECULAR MASS OLIGOMERIC AMYLOID BETA SPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID; OLIGOMER; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN TISSUE; CALCIUM CURRENT; CONFERENCE PAPER; DIMERIZATION; DROSOPHILA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GLIOSIS; HUMAN; IMMUNOREACTIVITY; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEURONS; PLAQUE, AMYLOID; PYRROLIDONECARBOXYLIC ACID;

MUS; MUS MUSCULUS;

EID: 79960882442     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0390857     Document Type: Conference Paper

References (45)

1. Hardy, J. and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388
2. Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185
3. Selkoe, D.J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498
4. Braak, H. and Braak, E. (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239-259
5. Selkoe, D.J. (1998) The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8, 447-453
6. Tseng, B.P., Kitazawa, M. and LaFerla, F.M. (2004) Amyloid β-peptide: the inside story. Curr. Alzheimer Res. 1, 231-239
7. Wirths, O., Multhaup, G. and Bayer, T.A. (2004) A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide: the first step of a fatal cascade. J. Neurochem. 91, 513-520
8. Selkoe, D.J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766
9. Klein, W.L. (2002) Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345-352
10. Harmeier, A., Wozny, C., Rost, B.R., Munter, L.M., Hua, H., Georgiev, O., Beyermann, M., Hildebrand, P.W., Weise, C., Schaffner, W. et al. (2009) Role of amyloid-β glycine 33 in oligomerization, toxicity, and neuronal plasticity. J. Neurosci. 29, 7582-7590
11. McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I. and Masters, C.L. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866
12. Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P. and Buxbaum, J.D. (2000) Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA, J. Am. Med. Assoc. 283, 1571-1577
13. Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B. and Selkoe, D.J. (2000) The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831-10839
14. Takahashi, R.H., Almeida, C.G., Kearney, P.F., Yu, F., Lin, M.T., Milner, T.A. and Gouras, G.K. (2004) Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592-3599
15. Klein, W.L., Krafft, G.A. and Finch, C.E. (2001) Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224
16. Selkoe, D.J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791
17. Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E. et al. (2004) Synaptic targeting by Alzheimer's-related amyloid β oligomers. J. Neurosci. 24, 10191-10200
18. Lacor, P.N., Buniel, M.C., Furlow, P.W., Sanz Clemente, A., Velasco, P.T., Wood, M., Viola, K.L. and Klein, W.L. (2007) Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796-807 (Pubitemid 46174498)
19. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453
20. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J. and Selkoe, D.J. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (Pubitemid 34288854)
21. Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Krafft, G.A. and Klein, W.L. (2003) Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 100, 10417-10422
22. Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E. and Rogers, J. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862
23. Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R.S., Harlan, J. et al. (2005) Globular amyloid β-peptide oligomer: a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95, 834-847
24. 1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci. 28, 788-797
25. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M. and Ashe, K.H. (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357
26. Ono, K., Condron, M.M. and Teplow, D.B. (2009) Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc. Natl. Acad. Sci. U.S.A. 106, 14745-14750
27. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A. et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842
28. Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J. and Ashe, K.H. (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84
29. Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J. and Sabatini, B.L. (2007) Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875 (Pubitemid 46438992)
30. Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T. et al. (2010) A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal Tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 30, 4845-4856
31. Gandy, S., Simon, A.J., Steele, J.W., Lublin, A.L., Lah, J.J., Walker, L.C., Levey, A.I., Krafft, G.A., Levy, E., Checler, F. et al. (2010) Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-β oligomers. Ann. Neurol. 68, 220-230
32. Lord, A., Englund, H., Soderberg, L., Tucker, S., Clausen, F., Hillered, L., Gordon, M., Morgan, D., Lannfelt, L., Pettersson, F.E. and Nilsson, L.N. (2009) Amyloid-β protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J. 276, 995-1006
33. Lord, A., Kalimo, H., Eckman, C., Zhang, X.Q., Lannfelt, L. and Nilsson, L.N. (2006) The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic miceNeurobiol. Aging 27, 67-77
34. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L. and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249
35. Selkoe, D.J., Abraham, C.R., Podlisny, M.B. and Duffy, L.K. (1986) Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J. Neurochem. 46, 1820-1834 (Pubitemid 16095489)
36. Gorevic, P.D., Goni, F., Pons-Estel, B., Alvarez, F., Peress, N.S. and Frangione, B. (1986) Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: immunohistological studies. J. Neuropathol. Exp. Neurol. 45, 647-664
37. Mori, H., Takio, K., Ogawara, M. and Selkoe, D.J. (1992) Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J. Biol. Chem. 267, 17082-17086
38. N3(pE), in senile plaques. Neuron 14, 457-466
39. 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 118, 487-496
40. Cynis, H., Scheel, E., Saido, T.C., Schilling, S. and Demuth, H.U. (2008) Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-β. Biochemistry 47, 7405-7413
41. Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M. et al. (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. Nat. Med. 14, 1106-1111
42. Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M. et al. (2010) Identification of low molecular weight pyroglutamate Aβ oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J. Biol. Chem. 285, 41517-41524
43. Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K. et al. (2003) Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U.S.A. 100, 2023-2028
44. Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Seubert, P., Freedman, S., Schenk, D. and Games, D. (2005) β-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 25, 9096-9101
45. Brody, D.L. and Holtzman, D.M. (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 31, 175-193